Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457104 | 0.93 | FAAH (0.44) | FAAHALPLTNFKDM4EULK1 | |
| SCHEMBL2456821 | 0.88 | FAAH (0.46) | FAAHTNFKDM4ENPC1ALDH1A1 | |
| SCHEMBL2456442 | 0.88 | FAAH (0.51) | FAAHALPLTNFKDM4ENPC1 | |
| SCHEMBL2458154 | 0.88 | FAAH (0.46) | FAAHTNFKDM4ENPC1ALDH1A1 | |
| SCHEMBL2458159 | 0.88 | FAAH (0.44) | FAAHULK1TRPV1 | |
| SCHEMBL2457202 | 0.87 | IGF1R (0.47) | FAAHALPLKDM4ENPC1ALDH1A1 | |
| SCHEMBL2454929 | 0.86 | ALPL (0.45) | FAAHALPLKDM4EULK1NPC1 | |
| SCHEMBL2459369 | 0.86 | FAAH (0.43) | FAAHTNFKDM4ENPC1ALDH1A1 | |
| SCHEMBL2456933 | 0.86 | FAAH (0.62) | FAAHTNFKDM4ENPC1ALDH1A1 | |
| SCHEMBL2457122 | 0.86 | FAAH (0.44) | FAAHTNFKDM4EULK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | claimed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | FAAH, FAAH2, CNR2 | FAAH 1/4885ALPL 4776/4885TNF 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.